NEW YORK (AP) -- Shares of cancer test maker Genomic Health Inc. plunged Thursday after the company reported disappointing sales of its Oncotype DX cancer test. THE SPARK: The Redwood City, Calif., ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that its Oncodetect™ molecular residual disease (MRD) test has received Medicare ...

We reiterate our Neutral recommendation on Genomic Health (GHDX) following its fourth-quarter 2011 results though the performance missed the Zacks Consensus Estimates on both fronts - revenue and ...

Thermo Fisher Scientific TMO recently received approval from the Food and Drug Administration (“FDA”) for its Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients who may be ...

Exact Sciences earns a BUY rating, driven by innovation in non-invasive cancer detection and the recent launch of Cancerguard. EXAS's core products—Cologuard, Oncotype DX, and OncoDetect—deliver ...

The investigators reported the results of a prospective, randomized, phase 3 trial studying the best individual therapy for women who have node-negative, estrogen-receptor‒positive (ER-positive) ...

Pertuzumab/Docetaxel/Carboplatin/Trastuzumab Regimen in Human Epidermal Growth Factor Receptor 2–Positive Early, Locally Advanced, and Oligometastatic Breast Cancer ...